Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
Cabaletta Bio (Nasdaq: CABA) announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, featuring new and updated clinical data on CABA-201, their 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The presentations will cover:
1. An oral presentation on the safety and efficacy of CABA-201 in patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials.
2. A poster presentation on correlative studies of CABA-201 in the same patient groups.
The ACR Convergence 2024 will be held from November 14-19, 2024, in Washington, D.C. Presentation materials will be available on Cabaletta Bio's website following the event.
Cabaletta Bio (Nasdaq: CABA) ha annunciato due presentazioni alla prossima American College of Rheumatology (ACR) Convergence 2024, che presenteranno nuovi dati clinici aggiornati su CABA-201, la loro terapia sperimentale con T cell CD19-CAR completamente umana contenente 4-1BB. Le presentazioni riguarderanno:
1. Una presentazione orale sulla sicurezza e l'efficacia di CABA-201 in pazienti con Miopatia Necrotizzante Mediata da Immunità e Lupus Eritematoso Sistemico, provenienti dagli studi clinici RESET-Myositis™ e RESET-SLE™.
2. Una presentazione poster su studi correlativi di CABA-201 negli stessi gruppi di pazienti.
L'ACR Convergence 2024 si terrà dal 14 al 19 novembre 2024 a Washington, D.C. I materiali delle presentazioni saranno disponibili sul sito web di Cabaletta Bio dopo l'evento.
Cabaletta Bio (Nasdaq: CABA) anunció dos presentaciones en la próxima Convergencia 2024 del American College of Rheumatology (ACR), que incluirán nuevos y actualizados datos clínicos sobre CABA-201, su terapia experimental con células T CD19-CAR totalmente humana que contiene 4-1BB. Las presentaciones cubrirán:
1. Una presentación oral sobre la seguridad y eficacia de CABA-201 en pacientes con Miopatía Necrotizante Mediata por Inmunidad y Lupus Eritematoso Sistémico, provenientes de los ensayos clínicos RESET-Myositis™ y RESET-SLE™.
2. Una presentación de póster sobre estudios correlativos de CABA-201 en los mismos grupos de pacientes.
La Convergencia de ACR 2024 se llevará a cabo del 14 al 19 de noviembre de 2024 en Washington, D.C. Los materiales de presentación estarán disponibles en el sitio web de Cabaletta Bio después del evento.
Cabaletta Bio (Nasdaq: CABA)는 다가오는 2024년 미국 류마티스 학회(ACR) 융합 행사에서 CABA-201에 대한 새로운 임상 데이터 발표를 포함해 두 개의 발표를 진행할 예정입니다. CABA-201은 4-1BB를 포함하는 완전 인간 CD19-CAR T 세포 연구 치료제입니다. 발표의 내용은 다음과 같습니다:
1. 면역매개괴사근병증 및 전신홍반루푸스 환자에서 CABA-201의 안전성 및 효능에 대한 구두 발표로 RESET-Myositis™ 및 RESET-SLE™ 임상 시험 결과를 포함합니다.
2. 동일한 환자 그룹에서 CABA-201의 상관 연구에 대한 포스터 발표입니다.
ACR Convergence 2024는 2024년 11월 14일부터 19일 사이에 워싱턴 D.C.에서 개최될 예정이며 발표 자료는 행사 후 Cabaletta Bio의 웹사이트에서 확인할 수 있습니다.
Cabaletta Bio (Nasdaq: CABA) a annoncé deux présentations lors de la prochaine Convergence 2024 du American College of Rheumatology (ACR), présentant de nouvelles données cliniques mises à jour sur CABA-201, leur thérapie expérimentale avec cellules T CD19-CAR entièrement humaine contenant 4-1BB. Les présentations couvriront :
1. Une présentation orale sur la sécurité et l'efficacité de CABA-201 chez des patients atteints de Myopathie Nécrosante Médiée par Immunité et de Lupus Érythémateux Systémique, provenant des essais cliniques RESET-Myositis™ et RESET-SLE™.
2. Une présentation par affiche sur des études corrélatives de CABA-201 dans les mêmes groupes de patients.
La Convergence ACR 2024 se tiendra du 14 au 19 novembre 2024 à Washington, D.C. Les documents de présentation seront disponibles sur le site Web de Cabaletta Bio après l'événement.
Cabaletta Bio (Nasdaq: CABA) hat zwei Präsentationen auf der bevorstehenden American College of Rheumatology (ACR) Convergence 2024 angekündigt, die neue und aktualisierte klinische Daten zu CABA-201, ihrer vollständig menschlichen CD19-CAR-T-Zell-Therapie mit 4-1BB, enthalten. Die Präsentationen werden folgende Themen behandeln:
1. Einen mündlichen Vortrag über die Sicherheit und Wirksamkeit von CABA-201 bei Patienten mit Immunvermittelter Nekrotisierender Myopathie und Systemischem Lupus Erythematodes aus den RESET-Myositis™ und RESET-SLE™ klinischen Studien.
2. Eine Posterpräsentation über korrelative Studien zu CABA-201 in denselben Patientengruppen.
Die ACR Convergence 2024 findet vom 14. bis 19. November 2024 in Washington, D.C. statt. Präsentationsmaterialien werden nach der Veranstaltung auf der Website von Cabaletta Bio verfügbar sein.
- Presentation of new and updated clinical data on CABA-201 at a major rheumatology conference
- CABA-201 is being evaluated in multiple ongoing clinical trials
- Potential for increased visibility and interest in Cabaletta Bio's research
- None.
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, which is being held at the Walter E. Washington Convention Center in Washington, D.C. from November 14-19, 2024. The presentations will feature new and updated clinical data on CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, which is being evaluated in multiple ongoing clinical trials in the RESET™ clinical development program.
Details of the presentations are as follows:
Oral Presentation:
Title: Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials
Abstract ID: 1857177
Date and Time: Sunday, November 17, 2024, 3:30 p.m. – 3:45 p.m. ET
Presenter: David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer, Cabaletta Bio
Poster Presentation:
Title: Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials
Abstract ID: 1866605
Date and Time: Saturday, November 16, 2024, 10:30 a.m. – 12:30 p.m. ET
Presenter: Daniel Nunez, Ph.D., Director, Computational Biology at Cabaletta Bio
Additional information, including the accepted abstracts, can be accessed on the ACR Convergence 2024 website. Presentation materials will be made available on the Posters & Publications section of the Company’s website following the event.
About CABA-201
CABA-201 is designed to deeply and transiently deplete CD19-positive cells following a one-time infusion, which may enable an “immune system reset” with the potential for durable remission without chronic therapy in patients with autoimmune diseases. Cabaletta is evaluating CABA-201 in multiple autoimmune conditions within five disease-specific company sponsored INDs including myositis (idiopathic inflammatory myopathy, or IIM), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), generalized myasthenia gravis (gMG), and pemphigus vulgaris (PV; a sub-study to evaluate CABA-201 without preconditioning).
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in myositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis and in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
FAQ
What is CABA-201 and what is it being developed for?
When and where will Cabaletta Bio (CABA) present data on CABA-201?
What types of presentations will Cabaletta Bio (CABA) give on CABA-201 at ACR Convergence 2024?
Where can investors find Cabaletta Bio's (CABA) presentation materials after the ACR Convergence 2024?
